Research programme: prostate cancer therapeutics - Avantogen Oncology

Drug Profile

Research programme: prostate cancer therapeutics - Avantogen Oncology

Alternative Names: BIO 133

Latest Information Update: 16 Mar 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Avantogen Oncology
  • Class
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 01 Jun 2006 Innovate Oncology is now a wholly owned subsidiary of Avantogen
  • 30 May 2006 Innovate Oncology has been acquired by Avantogen
  • 16 Sep 2005 Preclinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top